Appeal No. 1999-2330
Application No. 08/219,200
T cell proliferation in GVH disease. Specification page 26. In addition, B7Ig may be
used to crosslink the CD28 receptor, for example by contacting T cells with immobilized
B7Ig fusion protein, to assist in recovery of immune function after bone marrow
transplantation by stimulating T cell proliferation. Specification page 27.
The fusion proteins may be useful to regulate granulocyte macrophage colony
stimulating factor levels for the treatment of cancers, AIDS, and myelodysplasia. Id.
Moreover, the inhibition of anti-CD28 and anti B7mAbs on the cognate Th:B interaction
also provides the basis for employing the CD28Ig and B7Ig fusion proteins to treat
various autoimmune disorders associated with exaggerated B cell activation such as
insulin-dependent diabetes mellitus, myasthenia gravis, rheumatoid arthritis and
systemic lupus erythematosus (SLE). Specification, page 72. Methods for preparing
B7Ig fusions proteins are described in the specification at pages 52-55.
Grounds of Rejection
Claims 79-94 stand rejected under 35 U.S.C. § 112, first paragraph, for lack of
enablement.
Claims 79-94 stand rejected under 35 U.S.C. § 112, first paragraph and second
paragraph for failing to define the invention in a manner as to enable any person skilled
in the art to make and use the invention and for failing to point out and distinctly claim
the invention.
We reverse both rejections for the reasons herein.
4
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007